RxDoctor Payments Data

Nathan Bining, MD

Internal Medicine · Livonia, MINPI 1538102165

Payments from drug & device makers

$7,019in general payments, 2019–2025

Across 348 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$798
  • AbbVie$789
  • Pfizer$584
  • Indivior Inc.$451
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,019 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$32,814
Medicare patients
74
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide54$56,601
MounjaroTirzepatide50$52,456
FarxigaDapagliflozin Propanediol47$47,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$46,168
OzempicSemaglutide49$45,894
XareltoRivaroxaban45$37,511
EliquisApixaban37$36,141
JardianceEmpagliflozin15$24,030
Nurtec OdtRimegepant Sulfate21$23,613
OxycontinOxycodone Hcl13$22,805
TradjentaLinagliptin14$19,916
NucyntaTapentadol Hcl12$18,275
EntrestoSacubitril/Valsartan20$17,285
LinzessLinaclotide25$17,150
UbrelvyUbrogepant13$12,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$364$109,057104 claims
PfizerEliquis, Nurtec Odt$584$59,75458 claims
AstraZenecaFarxiga$798$47,00247 claims
GSKTrelegy Ellipta$1,218$46,16860 claims
Novo NordiskOzempic$93$45,89449 claims
Boehringer IngelheimJardiance, Tradjenta$88$43,94629 claims
Johnson & JohnsonXarelto$27$37,51145 claims
AbbVieLinzess, Ubrelvy, Creon$789$37,23150 claims
MerckJanuvia, Janumet$152$19,26524 claims
Collegium Pharmaceutical, Inc.Nucynta$118$18,27512 claims
NovartisEntresto$147$17,28520 claims
Indivior Inc.Suboxone$451$6,50712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →